JPMorgan Chase & Co. Has $81.14 Million Stock Position in ICU Medical, Inc. $ICUI

JPMorgan Chase & Co. lowered its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 10.6% during the third quarter, Holdings Channel reports. The fund owned 676,370 shares of the medical instruments supplier’s stock after selling 80,013 shares during the period. JPMorgan Chase & Co.’s holdings in ICU Medical were worth $81,137,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Millennium Management LLC raised its stake in shares of ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after acquiring an additional 690,694 shares during the last quarter. State Street Corp lifted its position in shares of ICU Medical by 3.2% during the second quarter. State Street Corp now owns 927,799 shares of the medical instruments supplier’s stock worth $122,609,000 after purchasing an additional 28,491 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ICU Medical by 16.9% during the third quarter. Dimensional Fund Advisors LP now owns 872,993 shares of the medical instruments supplier’s stock valued at $104,718,000 after purchasing an additional 126,072 shares during the last quarter. Ameriprise Financial Inc. grew its stake in shares of ICU Medical by 34.0% during the third quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock valued at $96,393,000 after purchasing an additional 203,746 shares during the last quarter. Finally, Schroder Investment Management Group increased its holdings in shares of ICU Medical by 25.2% in the third quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier’s stock valued at $93,246,000 after purchasing an additional 160,380 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Stock Down 4.0%

Shares of NASDAQ:ICUI opened at $125.29 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.39 and a quick ratio of 1.15. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of 6,267.63, a P/E/G ratio of 1.88 and a beta of 0.79. The company has a 50 day moving average of $146.73 and a 200-day moving average of $138.09. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $160.29.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The business had revenue of $535.94 million for the quarter, compared to analyst estimates of $541.20 million. During the same period in the prior year, the business posted $2.11 earnings per share. ICU Medical’s revenue was down 14.1% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, sell-side analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. Piper Sandler boosted their target price on ICU Medical from $172.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Finally, KeyCorp upped their price target on ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and an average target price of $179.33.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.